ALKS Q3 2025 Earnings — Alkermes plc Revenue & Financial Results | Market Cap Arena

ALKSAlkermes plc

$5B

Q3 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$394M+4.2% YoY

Gross Profit

$343M86.9% margin

Operating Income

$89M22.6% margin

Net Income

$83M21.0% margin

EPS (Diluted)

$0.49

QoQ Revenue Growth

+0.9%

Cash Flow

Operating Cash Flow

$102M

Free Cash Flow

$84M

Stock-Based Comp.

$25M

Balance Sheet

Total Assets

$2.3B

Total Liabilities

$596M

Stockholders' Equity

$1.7B

Cash & Equivalents

$616M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$394M	$378M	+4.2%
Gross Profit	$343M	$315M	+8.7%
Operating Income	$89M	$105M	-15.0%
Net Income	$83M	$92M	-10.4%

Revenue Segments

Product

$317M50%

Vivitrol

$121M19%

L Y B A L V I

$98M15%

Aristada And Aristada Initio

$98M15%